exact test) at diagnosis and relapse are shown for patients receiving standard upfront radiotherapy and chemotherapy before and after (in parentheses) adjustment for multiple testing (Bonferroni correction). Cross-hatched boxes, not relevant. (B) Assessment of intra-tumoral molecular heterogeneity supports the development of combined MYC family gene amplification and TP53 mutation by both clonal enrichment and de novo acquisition. Estimated percentages of MYC/MYCN-amplified (by iFISH; >5% cells, dashed red line) and TP53 mutated (estimated peak heights, mutant versus wild-type) tumor cells at diagnosis (D) and relapse (R) in four patients with available material support clonal enrichment (e.g. MYCN amplification in patients 8 & 10) and de novo acquisition of combined defects at relapse (e.g. MYC amplification in patient 12; MYCN amplification and TP53 mutation in patient 22). Patient 22 showed no evidence of TP53 mutation at diagnosis, based on >1900 next-generation sequencing reads (*expanded box). All TP53 mutated tumors also displayed chromosome 17p loss. (bottom grid) grey, present; white, absent; cross-hatched, not relevant. 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Analysis of Molecular Subgroup Status by DNA Methylation Profiling
(A) Identification of subgroup membership using metagene patterns of the diagnostic and relapse samples within our study cohort. 5 metagenes (F1 to F5) were identified in the training cohort of 225 medulloblastomas using consensus NMF clustering; 2 metagenes (F3 and F4) identified the SHH subgroup, consistent with recent reports of heterogeneity within the SHH subgroup (Kool et al., 2014) . Metagene projection (Tamayo et al., 2007) was employed to derive metagene values for the study cohort that were subsequently used to assign subgroup and assess classification confidence. Samples are shown in rows; samples confidently assigned to a subgroup are labelled by their assignation (red, MB SHH ; blue, MB WNT ; yellow, MB Group3 ; green, MB Group4 ). Samples within our study cohort that were unable to be confidently assigned (confidence score < 0.7) are labelled grey (MB NOS ). High, intermediate and low metagene values are shown red, white and blue, respectively. (B) Comparison of metagene patterns for diagnostic and relapse samples within our study cohort, with metagene patterns from the training cohort. Bi-plot of principal component analysis of combined training, diagnostic and relapsing cohorts. Arrows show projections of five metagenes along first and second principal components. Individual cases are plotted by their principal component scores. Training cohort cases are shown as squares, diagnostic cohort cases as diamonds and relapsing cohort cases as circles. Additionally, cases are labelled by their assigned subgroup (red, MB SHH ; blue, MB WNT ; yellow, MB Group3 ; green, MB Group4 . Cases with an unclear subgroup (confidence score < 0.7) are labelled grey (MB NOS )) and were not included in our subgroup analysis. Finally, training cohort cases are shown with transparency, to emphasise the members of our study cohort.
Analysis of TP53 Status in Clinical Samples
TP53 status was assessed by direct polymerase chain reaction (PCR) based DNA sequence analysis of exons 4-9 using the following FAST PCR conditions: 95ºC for 40s; 35 cycles of 94ºC for 0s, then 64ºC for 15s; 72ºC for 45s (see below for primer sequences). Cases positive for P53 nuclear staining on immunohistochemistry (IHC) with no apparent mutation had an extended screen of exons 2-11 (see below for primer sequences). One tumor pair (patient 22, Figure S2B ) that showed acquisition of a TP53 mutation in exon 5 was assessed by next-generation sequencing using primers for exon 5 as previously described (Grossmann et al., 2011) . Primer validation was performed according to manufacturer's instructions (Fluidigm) and PCR products checked using a 2100 BioAnalyzer (Agilent Technologies). Barcoded PCR products were pooled and run in a single sequencing experiment on a Roche 454 FLX sequencer (454 Life Sciences).
Location
Forward primer 5'-3' Reverse primer 5'-3' (Boland et al., 1998; Jung et al., 2004; Langdon et al., 2006) . Polyploidy, was defined as a modal score > 2 at ≥ 2 centromeric loci examined by iFISH (chromosomes 2, 8 and 17).
Trp53 Mutational Analysis
Genomic DNA was extracted from cell lines, tumors and where available, normal brain tissue using QIAamp DNA Mini kit (Qiagen). PCR amplification of exons 5-9 was performed using primers detailed below. Products were sequenced with the original PCR primers using the BigDye Terminator Cycle Sequencing Kit and an ABI 3730 Genetic Analyzer (Applied Biosystems). Sequences were analyzed using Mutation Surveyor software (SoftGenetics).
Primers for Trp53 PCR reaction
Location Forward primer 5'-3' Reverse primer 5'-3' Exon 5/6 GATCGTTACTCGGCTTGTCC AAGACGCACAAACCAAAACA Exon 7 CTATAGCCAGCCATTCCCG AGGCAGAAGCTGGGGAAG Exon 8/9 TACACACAGTCAGGATGGGG ATGCGAGAGACAGAGGCAAT
Real-time PCR
Total RNA was isolated from cells or tumor tissue using the miRNAeasy minikit (Qiagen) and cDNA prepared using Superscript II Reverse Transcriptase (Life Technologies). Quantitative PCR (QT-PCR) was performed in triplicate using Taqman Gene Expression mix (Life Technologies) and gene-specific primers for Cdkn1a (Mm04205640), Mdm2 (Mm01233136), MYCN (Hs00232074) and Actb (Mm00607939) (Life Technologies). Relative expression was calculated according to the ΔΔCt relative quantification method against the average expression of control cells treated with ethanol or vehicle treated tumors.
In Situ Proximity Ligation Assay
Duolink in situ proximity ligation assay (PLA; Olink Bioscience) was performed on GTML/Trp53 KI/KI neurospheres. Cells were fixed in 4% paraformaldehyde for 20 min, permeabilized with 0.5% Triton X-100, and blocked with 1% BSA for 30 min at room temperature followed by incubation with paired primary antibodies, MYCN (OP-13, Merck-Millipore) with Aurora-A (Genetex), overnight at 4ºC. PLA detection was performed as recommended by the manufacturer. Images were taken and analyzed using the Zeiss LSM700 confocal microscope and analyzed using DuoLink image analysis software.
Quantitative In Situ RNA Analysis
Dual color RNA in situ hybridization was performed using the RNAscope 2-plex Chromogenic Reagent Kit (Advanced Cell Diagnostics, ACD) according to the manufacturer's instructions. Paired double-Z oligonucleotide probes were designed against Cdkn1a using custom software as previously described (Wang et al., 2012) . Cdkn1a-specific RNA target Z probe pairs (20) targeted bps 19 through 1240 of the Cdkn1a cDNA sequence (NM_007669.4). Probe sets specific for mouse Ubc (ubiquitin C), Polr2a (DNAdirected RNA polymerase II subunit RPB1) and Ppib (Peptidylprolyl Isomerase B, Cyclophilin B) and dapB (dihydrodipicolinate reductase) gene from B. subtilis were also used. FFPE tissue blocks were sectioned at 4 µm. Slides were baked for 1 hr at 60°C prior to use. After de-paraffinization and dehydration, the tissues were air dried and treated with peroxidase blocker before boiling at 100-104 °C in a pre-treatment solution for 15 min. Protease was then applied for 30 min at 40 °C. Target probes for each two-gene combination were premixed and hybridized together for 2 hr at 40 °C, followed by a series of signal amplification and washing steps. All hybridizations at 40 °C were performed in a HybEZ Hybridization System (ACD). Following the RNAscope assay, samples were counterstained for 2 minutes with 50% Gill's Hematoxylin diluted in dH 2 0. Hybridization signals were detected by sequential chromogenic reactions using red and green chromogens, and RNA staining signal was identified as red and green punctate dots. Each sample was quality controlled for RNA integrity with a probe specific to the Ppib housekeeping gene only samples with an average of >4 dots per cell were included for analysis. Negative control background staining was evaluated using a probe specific to the bacterial dapB gene; only samples with an average of <1 dot per 10 cells were included for analysis. Cdkn1a expression was quantitated using RNAscope SpotStudio (Wang et al., 2013) . Outline regions of interest (ROI) were classified into individual dots and clustered dots within the ROI. Hematoxylin-stained nuclei and cell boundaries were also detected. RNAscope Cdkn1a mRNA images were batch analyzed after selecting appropriate ROIs manually. For each whole slide image, three ROIs were selected to represent the entire tumor section. The number of cells analyzed ranged from 4,000 to 43,000.
Pharmacokinetic analysis of MLN8237 and GDC-0449
Calibration and quality control solutions were prepared in dimethyl sulfoxide (DMSO). MLN8237 and GDC-0449 calibration standards used for spiking were prepared to give final matrix concentrations of 2-10000 nM. Quality Control (QC) standards were also prepared to give a final concentration of 25, 250, 750 and 2500 nM. A stock solution of Olomoucine (Sigma-Aldrich) internal standard (IS) was prepared in DMSO at a concentration of 1 mM and further diluted in methanol to give a working IS solution of 250 nM for quenching. Plasma and tissue samples were homogenized in either 3 or 5 ml/g phosphate buffered. 100 µl aliquots of untreated mouse plasma or tissue homogenates were spiked with 10 µl of the appropriate calibration or QC standard solutions. 100 µl aliquots of the unknown samples were spiked with 10 µl DMSO. Where necessary, plasma and tissue samples were diluted with untreated (blank) matrix. Spiked protein calibration standards, QCs and unknown samples were precipitated with 300 µL methanol containing 250 nM IS. Blank samples were prepared by spiking 100 µl untreated plasma/tissue with 10 µl DMSO and protein precipitated with 300 µl methanol. After centrifugation, supernatants were analyzed by liquid chromatography with tandem mass spectrometry detection (LC-MS/MS) using a Xevo TQ-S mass spectrometer coupled with an Acquity ultra-performance liquid chromatography UPLC H-class system (Waters). Chromatography was carried out using a Phenomenex C18 X-B column (2.6 µm, 50 mm x 2.1 mm ID) with a gradient mobile phase consisting of 0.1 % formic acid and methanol. 2ml of sample was injected on to the column using a flow rate of 0.6 ml/min with a 5 minute run time. Both analytes and IS were ionized using electrospray interface in positive ion mode. Detection was via tandem mass spectrometry (MS/MS) in multiple reaction monitoring (MRM) mode. The transitions m/z 519. 12-139.04, 421.11-110.87 and m/z 299.19-177.29 were monitored for MLN8237, GDC-0449 and IS respectively. Data acquisition was performed using Targetlynx. The assay was linear over the range 2-10,000 nM.
